PHARMACOTHERAPEUTICS FOR ADVANCED
PRACTICE NURSES AND PHYSICIAN
ASSISTANTS 4TH EDITION 2024/2025 ALL
CHAPTERS COVERED
_______________________________________
Azithromycin dosing requires the first day's dose be twice those of the other 4 days of the
prescription. This is considered a loading dose. A loading dose:
A.
Rapidly achieves drug levels in the therapeutic range
B.
Requires four to five half-lives to attain
C.
Is influenced by renal function
D.
Is directly related to the drug circulating to the target tissues
A
The point in time on the drug concentration curve that indicates the first sign of a
therapeutic effect is the:
A.
Minimum adverse effect level
B.
Peak of action
C.
Onset of action
D.
Therapeutic range
C
,Phenytoin requires a trough level be drawn. Peak and trough levels are done:
A.
When the drug has a wide therapeutic range
B.
When the drug will be administered for a short time only
C.
When there is a high correlation between the dose and saturation of receptor sites
D.
To determine if a drug is in the therapeutic range
D
A laboratory result indicates the peak level for a drug is above the minimum toxic
concentration. This means that the:
A.
Concentration will produce therapeutic effects
B.
Concentration will produce an adverse response
C.
Time between doses must be shortened
D.
Duration of action of the drug is too long
B
Drugs that are receptor agonists may demonstrate what property?
A.
Irreversible binding to the drug receptor site
B.
Up-regulation with chronic use
C.
Desensitization or down-regulation with continuous use
D.
Inverse relationship between drug concentration and drug action
,C
Drugs that are receptor antagonists, such as beta blockers, may cause:
A.
Down-regulation of the drug receptor
B.
An exaggerated response if abruptly discontinued
C.
Partial blockade of the effects of agonist drugs
D.
An exaggerated response to competitive drug agonists
B
Factors that affect gastric drug absorption include:
A.
Liver enzyme activity
B.
Protein-binding properties of the drug molecule
C.
Lipid solubility of the drug
D.
Ability to chew and swallow
C
Drugs administered via intravenous (IV) route:
A.
Need to be lipid soluble in order to be easily absorbed
B.
Begin distribution into the body immediately
C.
Are easily absorbed if they are nonionized
D.
May use pinocytosis to be absorbed
, B
When a medication is added to a regimen for a synergistic effect, the combined effect of
the drugs is:
A.
The sum of the effects of each drug individually
B.
Greater than the sum of the effects of each drug individually
C.
Less than the effect of each drug individually
D.
Not predictable, as it varies with each individual
B
Which of the following statements about bioavailability is true?
A.
Bioavailability issues are especially important for drugs with narrow therapeutic ranges or
sustained release mechanisms.
B.
All brands of a drug have the same bioavailability.
C.
Drugs that are administered more than once a day have greater bioavailability than drugs
given once daily.
D.
Combining an active drug with an inert substance does not affect bioavailability
A
Which of the following statements about the major distribution barriers (blood-brain or
fetal-placental) is true?
A.
Water soluble and ionized drugs cross these barriers rapidly.
B.
The blood-brain barrier slows the entry of many drugs into and from brain cells.
PRACTICE NURSES AND PHYSICIAN
ASSISTANTS 4TH EDITION 2024/2025 ALL
CHAPTERS COVERED
_______________________________________
Azithromycin dosing requires the first day's dose be twice those of the other 4 days of the
prescription. This is considered a loading dose. A loading dose:
A.
Rapidly achieves drug levels in the therapeutic range
B.
Requires four to five half-lives to attain
C.
Is influenced by renal function
D.
Is directly related to the drug circulating to the target tissues
A
The point in time on the drug concentration curve that indicates the first sign of a
therapeutic effect is the:
A.
Minimum adverse effect level
B.
Peak of action
C.
Onset of action
D.
Therapeutic range
C
,Phenytoin requires a trough level be drawn. Peak and trough levels are done:
A.
When the drug has a wide therapeutic range
B.
When the drug will be administered for a short time only
C.
When there is a high correlation between the dose and saturation of receptor sites
D.
To determine if a drug is in the therapeutic range
D
A laboratory result indicates the peak level for a drug is above the minimum toxic
concentration. This means that the:
A.
Concentration will produce therapeutic effects
B.
Concentration will produce an adverse response
C.
Time between doses must be shortened
D.
Duration of action of the drug is too long
B
Drugs that are receptor agonists may demonstrate what property?
A.
Irreversible binding to the drug receptor site
B.
Up-regulation with chronic use
C.
Desensitization or down-regulation with continuous use
D.
Inverse relationship between drug concentration and drug action
,C
Drugs that are receptor antagonists, such as beta blockers, may cause:
A.
Down-regulation of the drug receptor
B.
An exaggerated response if abruptly discontinued
C.
Partial blockade of the effects of agonist drugs
D.
An exaggerated response to competitive drug agonists
B
Factors that affect gastric drug absorption include:
A.
Liver enzyme activity
B.
Protein-binding properties of the drug molecule
C.
Lipid solubility of the drug
D.
Ability to chew and swallow
C
Drugs administered via intravenous (IV) route:
A.
Need to be lipid soluble in order to be easily absorbed
B.
Begin distribution into the body immediately
C.
Are easily absorbed if they are nonionized
D.
May use pinocytosis to be absorbed
, B
When a medication is added to a regimen for a synergistic effect, the combined effect of
the drugs is:
A.
The sum of the effects of each drug individually
B.
Greater than the sum of the effects of each drug individually
C.
Less than the effect of each drug individually
D.
Not predictable, as it varies with each individual
B
Which of the following statements about bioavailability is true?
A.
Bioavailability issues are especially important for drugs with narrow therapeutic ranges or
sustained release mechanisms.
B.
All brands of a drug have the same bioavailability.
C.
Drugs that are administered more than once a day have greater bioavailability than drugs
given once daily.
D.
Combining an active drug with an inert substance does not affect bioavailability
A
Which of the following statements about the major distribution barriers (blood-brain or
fetal-placental) is true?
A.
Water soluble and ionized drugs cross these barriers rapidly.
B.
The blood-brain barrier slows the entry of many drugs into and from brain cells.
